A new study showed that propylthiouracil and methimazole use during pregnancy was associated with increased risk of congenital malformations. Intriguingly, the authors identified dose-dependent effects for methimazole but not propylthiouracil, whereas the recommended switch from methimazole to propylthiouracil during early pregnancy did not reduce the risk of congenital malformations.